Two Sigma Investments LP Has $98.07 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Two Sigma Investments LP reduced its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 34.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 733,918 shares of the life sciences company's stock after selling 380,248 shares during the quarter. Two Sigma Investments LP owned about 0.46% of Illumina worth $98,073,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ILMN. Taconic Capital Advisors LP purchased a new position in shares of Illumina during the fourth quarter worth $668,000. Tidal Investments LLC increased its stake in shares of Illumina by 740.3% in the 4th quarter. Tidal Investments LLC now owns 37,385 shares of the life sciences company's stock valued at $4,996,000 after purchasing an additional 32,936 shares in the last quarter. Tema Etfs LLC purchased a new position in Illumina during the fourth quarter valued at $1,903,000. Scientech Research LLC purchased a new position in Illumina during the fourth quarter valued at $1,490,000. Finally, Siemens Fonds Invest GmbH increased its position in shares of Illumina by 84.8% during the fourth quarter. Siemens Fonds Invest GmbH now owns 6,119 shares of the life sciences company's stock worth $818,000 after purchasing an additional 2,807 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Insider Transactions at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the acquisition, the chief financial officer now directly owns 24,906 shares in the company, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.60% of the company's stock.

Illumina Stock Performance

ILMN traded down $0.17 during trading hours on Friday, hitting $80.37. 1,536,714 shares of the stock were exchanged, compared to its average volume of 2,321,525. The stock has a 50-day simple moving average of $78.14 and a 200-day simple moving average of $109.01. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The stock has a market cap of $12.72 billion, a price-to-earnings ratio of -10.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The business's revenue was down 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.98 earnings per share. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ILMN shares. Morgan Stanley decreased their target price on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and dropped their price objective for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Guggenheim decreased their target price on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Robert W. Baird lowered their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a research note on Wednesday, March 5th. Finally, HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Illumina has a consensus rating of "Moderate Buy" and an average price target of $128.15.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.